AVXL just took a damaging blow from Rett EXCELLENCE.
It wasn't a "fail"; it was a marginal stat.sig. miss, due to an unfortunate randomization and perhaps undersized trial.
Once the FDA sees all of the evidence of efficacy and QOL benefits, seizure reduction with an excellent safety profile with both trials, plus extensions, the drug will be approved for Rett, perhaps yet this year.